Count on formulations biz to outpace API biz: Biocon Group CEO Peter Bains | Interviews

Biocon delves into the evolving dynamics of the biosimilar market, with a concentrate on its methods and outlook for 2024-25 (FY25). PETER BAINS, group chief government officer of Biocon, in a video interview with Aneeka Chatterjee, discusses their efforts to achieve market share in key areas, the influence of decrease energetic pharmaceutical ingredient (API) costs, and progress plans for biosimilars and generics. He additionally highlights Biocon’s strategic partnerships, debt discount plans, and the anticipated restoration of their contract analysis enterprise. Edited excerpts:

Biosimilar earnings earlier than curiosity, tax, depreciation, and amortisation (Ebitda) margin reverted to 24 per cent regardless of excessive transition

First Printed: Could 21 2024 | 11:36 PM IST